# Initial review — P03

Morgan Reed, fictional commercial analytics lead at a hypothetical specialty-software vendor. This is an AI simulation, not real stakeholder validation. This initial review precedes any clarification replies; linked sources were not browsed.

## R38

**Outcome:** Next action and owner are clear without clarification. Confidence: high. No apparent interpretation errors.

The sales operations owner should reconcile the 44 supplied open Gastroenterology opportunity IDs with the source snapshot, supply its capture timestamp, and confirm or correct stages and close dates. The return should show resulting open and overdue counts and ACV, so Morgan can interpret the $4,983,000 supplied overdue amount against verified source status. Avery Brooks should retain the reproduced Gastroenterology/45378/year calculations and confirm pinned snapshot provenance. Sales operations owns opportunity status and freshness; BI owns reproducibility and provenance. Account discovery and applicability remain pending before a commercial recommendation.

**Evidence missing from the handoff:** The opportunity IDs and row-level fields; source capture timestamp and current-status confirmation; calculation output/audit trail and verified snapshot provenance; account discovery and evidence connecting reimbursement changes to software need. These omissions define the work to perform and do not prevent understanding the instruction.

**Clarification needed:** No. No clarification questions.

**Business questions for the next check:** Can all 44 IDs be matched, and when was the snapshot captured? Which stages or close dates need correction, and what totals remain? Can BI verify provenance and preserve the calculation trail? What subsequent discovery would establish an applicable account need?

**Source/format cues:** Structured numeric comparison and explicit owner/check sections; commit-pinned GitHub CSV, mart, receipt, certification-log links and a Databricks-named release folder; explicit synthetic-data and local-reproduction boundaries.

## R64

**Outcome:** Next action and owner are clear without clarification. Confidence: high. No apparent interpretation errors.

The sales operations lead should reconcile the 57 supplied open Pain Management opportunity IDs with the source snapshot, obtain its capture timestamp, and confirm or correct stages and close dates. The return should show resulting open and overdue counts and ACV, so Morgan can assess the $3,211,200 supplied overdue amount against verified source status. Avery Brooks should retain the reproduced Pain Management/64483 calculations and verify pinned snapshot, exported hash, and receipt provenance. Sales operations owns opportunity status and freshness; BI owns calculation and artifact traceability. Account discovery remains pending before planning or a commercial recommendation.

**Evidence missing from the handoff:** The opportunity IDs and row-level fields; source capture timestamp and current-status confirmation; captured app export, exported hash values, calculation audit trail and verified provenance; account applicability and discovery evidence. These are next-check inputs or findings, not unclear instructions.

**Clarification needed:** No. No clarification questions.

**Business questions for the next check:** Can all 57 IDs be matched, and when was the snapshot captured? Which stages or dates need correction, and what totals remain? Can BI connect the reproduced calculations to pinned snapshots, export hashes, and receipt? What subsequent discovery would establish an applicable account need?

**Source/format cues:** Structured comparison and explicit ownership/check sections; app-export and coordinator-capture language; hash/receipt and browser-usability disclosures; a procedure-view application link and payment-check document alongside commit-pinned artifacts. The numeric pressure score is expressly labeled unvalidated.

## Comparison

Both memos are actionable for verification, while commercial interpretation remains gated by missing evidence. Their explicit synthetic-data limits and distinction between reimbursement and software ACV prevent an apparent inference of need or outreach priority. R64 supplies more artifact-traceability detail and explicitly says no CRM update is requested. No study methods or outcomes were inferred from these differences.